Starting or Changing Therapy – A Prospective Study Exploring Antiretroviral Decision–Making

Fehr, Jan; Nicca, Dunja; Sendi, Parham; Wolf, Eva; Wagels, Thomas; Kiss, Alexander; Bregenzer, Thomas; Vernazza, Pietro; Jäger, H.; Spirig, Rebecca; Battegay, Manuel

doi:10.1007/s15010-005-4141-1

Cited by 19 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those authors who conceptualized readiness as decision-making measured readiness by whether participants had declined or accepted treatment [26–29], by the length of time to accepting care [30], or by qualitative information on why participants declined/accepted treatment [31]. …”

Section: Resultsmentioning

confidence: 99%

Readiness: The State of the Science (or the Lack Thereof)

Grimes

2010

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

HIV treatment guidelines state that patients' readiness should be assessed before initiating highly active antiretroviral therapy (HAART) to assure adherence. None of the guidelines provide a way to measure readiness. Therefore, this article sought to review the literature on readiness to determine if there was a viable predictor of adherence. Twenty-seven articles were reviewed. Nine described studies that examined the relationship between a measure of readiness and HAART adherence. No readiness measure demonstrated clinical utility as a predictor of adherence. Study flaws included small sample sizes (only one study >100 patients), short follow-up periods (all ≤1 year and six were ≤5 months, four ≤1 month), measures of readiness that related poorly to adherence, and inconsistent adherence measures (eight different measures were used by the researchers). Neither the guidelines nor the literature will help clinicians judge who should initiate HAART and who should delay treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Readiness: The State of the Science (or the Lack Thereof)

Grimes

2010

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

show abstract

“…Our data suggest that patient beliefs and perceptions about medication were powerful predictors of persistence of the regimen, and even more important than clinical and sociodemographic factors in the case of mild adverse events. It is known that HIV‐infected patients face a number of challenges around the decision to commence treatment, such as the risk of side effects, adherence to life‐long treatment and perhaps stigma, balanced against the feeling of being protected and healthy [28–30], and some patients are not willing or are reluctant to initiate cART [31–33]. Thus, some patients have a more negative attitude towards cART than might be assumed from consideration of clinical or demographic indicators alone.…”

Section: Discussionmentioning

confidence: 99%

The influence of patient beliefs and treatment satisfaction on the discontinuation of current first‐line antiretroviral regimens

Casado¹,

Marín²,

Romero³

et al. 2015

HIV Medicine

View full text Add to dashboard Cite

show abstract

“…29 In addition, patient involvement in the treatment decision-making process is likely to influence initial choices as well. 30,31 Patients receiving care in the western US were more likely to be prescribed ''other'' regimens and more than 3 agents in combination. Regional variation in clinical care has been a subject of intense study for decades.…”

Section: Discussionmentioning

confidence: 99%